Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Earmarked Funds For Premarket Review Supported By Device Associations

This article was originally published in The Gray Sheet

Executive Summary

Senate and House conferees should retain the $7 mil. and 45 FTEs earmarked by the Senate version of the FY 2000 agriculture appropriations bill (S 1233) for medical device reviews, the Health Industry Manufacturers Association urges in a Sept. 13 letter to the Senate Appropriations Committee.

You may also be interested in...



Senate FDA Budget Bill Mandates $1 Mil. For Reprocessing Oversight

A Democratic amendment contained in the Senate agriculture appropriations bill (S 1233) for fiscal year 2000 directs FDA's Center for Devices and Radiological Health to allocate $1 mil. of its budget for overseeing the practice of medical device reprocessing. The legislation cleared the chamber by voice vote on Aug. 4.

CBER's David Feigal Named FDA Device Center Director May 4

FDA Commissioner Jane Henney's appointment of David Feigal, Jr., MD/MPH, to head the Center for Devices and Radiological Health once again returns industry to the position of determining whether a new device center director views FDA's regulation of devices in a different light than drugs and biologics.

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

UsernamePublicRestriction

Register

OM004967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel